Dr. Schulte holds a PhD in neuroscience from the University of British Columbia, Vancouver, and completed his postdoctoral work at the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology (MIT).  His research efforts in both academic and industrial settings have been applied to the discovery of small molecule therapeutics for neurodegenerative disease in transgenic models.  He has developed techniques for drug discovery in primary neurons expressing disease transgenes, which he optimized at the Broad Institute, and subsequently screened on libraries at the Harvard Medical School ICCB-L and DRSC.  From this research, Dr. Schulte has brought leads into hit confirmation and preclinical validation, and onward to first-in-human pilot study design at the Harvard Catalyst program for translational medicine.  At Oxalys Pharmaceuticals, he is currently focused on drug discovery and therapeutic development for Parkinson’s disease and polyglutamine disorders.